USP7
USP7 (Ubiquitin C-terminal hydrolase 7) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Multiple myeloma and Burkitt lymphoma.
Overview
Hydrolase that deubiquitinates target proteins such as ARMC5, FOXO4, DEPTOR, KAT5, p53/TP53, MDM2, ERCC6, DNMT1, UHRF1, PTEN, KMT2E/MLL5 and DAXX. Together with DAXX, prevents MDM2 self-ubiquitination and enhances the E3 ligase activity of MDM2 towards p53/TP53, thereby promoting p53/TP53 ubiquitination and proteasomal degradation. Deubiquitinates p53/TP53, preventing degradation of p53/TP53, and enhances p53/TP53-dependent transcription regulation, cell growth repression and apoptosis.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant. IntOGen calls it a driver in 2 cohorts (0 activating, 2 loss-of-function), covering Burkitt Lymphoma, Plasma Cell Myeloma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · USP7 (Ubiquitin C-terminal hydrolase 7) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Multiple myeloma and Burkitt lymphoma.
- 1 · What it is
USP7 (Ubiquitin C-terminal hydrolase 7) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Multiple myeloma and Burkitt lymphoma.
- 2 · What goes wrong in cancer
Hydrolase that deubiquitinates target proteins such as ARMC5, FOXO4, DEPTOR, KAT5, p53/TP53, MDM2, ERCC6, DNMT1, UHRF1, PTEN, KMT2E/MLL5 and DAXX.
- 3 · How drugs use it
No product in this corpus aims at USP7 yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
External identifiers
Sources: HGNC HGNC:12630 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q93009 (protein name, function text, keywords and locations (REST API)); CIViC gene USP7 (1 evidence items, 0 assertions, 1 variants; diseases: Burkitt Lymphoma (GraphQL API, CC0)); IntOGen USP7 (driver in 2 cohorts (Act 0, LoF 2); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Hydrolase that deubiquitinates target proteins such as ARMC5, FOXO4, DEPTOR, KAT5, p53/TP53, MDM2, ERCC6, DNMT1, UHRF1, PTEN, KMT2E/MLL5 and DAXX. Together with DAXX, prevents MDM2 self-ubiquitination and enhances the E3 ligase activity of MDM2 towards p53/TP53, thereby promoting p53/TP53 ubiquitination and proteasomal degradation. Deubiquitinates p53/TP53, preventing degradation of p53/TP53, and enhances p53/TP53-dependent transcription regulation, cell growth repression and apoptosis. Deubiquitinates p53/TP53 and MDM2 and strongly stabilises p53/TP53 even in the presence of excess MDM2, and also induces p53/TP53-dependent cell growth repression and apoptosis. Deubiquitination of FOXO4 in presence of hydrogen peroxide is not dependent on p53/TP53 and inhibits FOXO4-induced transcriptional activity. In association with DAXX, is involved in the deubiquitination and translocation of PTEN from the nucleus to the cytoplasm, both processes that are counteracted by PML. Location: Nucleus; Cytoplasm; Nucleus, PML body; Chromosome (UniProt). Locus 16p13.2 (HGNC).
- Multiple myeloma: IntOGen driver in 1 cohort (PCM)
- Burkitt lymphoma: CIViC evidence names this disease; IntOGen driver in 1 cohort (BL)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it a loss-of-function (LoF) driver in 2 cohorts; CIViC holds 1 clinical evidence items on its variants; UniProt keyword "DNA repair". Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"USP7" OR ABSTRACT:"USP7" OR TITLE:"ubiquitin specific peptidase 7" OR ABSTRACT:"ubiquitin specific peptidase 7" OR TITLE:"Ubiquitin C-terminal hydrolase 7" OR ABSTRACT:"Ubiquitin C-terminal hydrolase 7" OR TITLE:"HAUSP" OR ABSTRACT:"HAUSP") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about USP7, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetBCL7A
Shares Burkitt lymphoma, CIViC, IntOGen, Multiple myeloma.
- TargetGNAI2
Shares Burkitt lymphoma, CIViC, IntOGen.
- TargetTFAP4
Shares Burkitt lymphoma, CIViC, IntOGen.
- TargetSIN3A
Shares Burkitt lymphoma, CIViC, IntOGen.
- TargetCHD8
Shares Burkitt lymphoma, CIViC.
- TargetEIF4A1
Shares Burkitt lymphoma, CIViC.
- TargetHNRNPU
Shares Burkitt lymphoma, CIViC.
- TargetWNK1
Shares Burkitt lymphoma, CIViC.